Polish acquisition of Biofarm signals rising valuation premiums in Romanian M&A market

Polish investors have acquired Romanian pharmaceutical firm Biofarm at a valuation of 4x turnover and 12x net profit. This transaction suggests a growing 'Romanian premium' driven by aggressive Polish capital inflows, signaling potential shifts in local asset pricing and competitive dynamics for domestic entrepreneurs.